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Abstract
Background: Although neuroendocrine tumors are most commonly found in the digestive system, neuroendocrine
tumors originating from the bile duct are rare, and neuroendocrine carcinomas derived from the perihilar bile duct are
extremely rare. This report presents the clinical course and clinicopathological features of neuroendocrine carcinomas
arising from the extrahepatic bile duct.
Case presentation: A 70-year-old Japanese woman was preoperatively diagnosed with perihilar cholangiocarcinoma,
and a radical resection with an extended left hepatic lobectomy and a choledochojejunostomy was performed. From
the histopathological findings, we diagnosed the tumor as a neuroendocrine carcinoma of the bile duct (small cell
type) with lymph node metastasis. The patient was treated with the same adjuvant chemotherapy as that used for
small cell carcinoma of the lung. At 10 months after surgery, there was no recurrence of the disease.
Conclusion: Neuroendocrine carcinoma of the extrahepatic biliary tracts is a very rare and highly malignant disease
with a poor prognosis. A multidisciplinary approach could improve the prognosis for this neoplasm.
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Background
The World Health Organization (WHO) classification
system (2010) defines neoplasms with neuroendocrine
differentiation as neuroendocrine tumors (NETs). These
are stratified as NET Grade 1 (G1), NET Grade 2 (G2),
and neuroendocrine carcinoma (NEC) [1]. Although
NETs are most commonly found in the digestive system,
NETs originating from the extrahepatic bile duct are
rare, and NECs arising from the perihilar bile duct are
extremely rare [2]. In this report, we present the clinical
course and clinicopathological features of a case of NEC
originating from the extrahepatic bile duct, as well as
the results of a literature review on this subject.
Case presentation
A 70-year-old Japanese woman presented to our hospital
for investigation of a chief complaint of jaundice. The pa-
tient had no family history of cancer. A physical examin-
ation revealed no remarkable findings. Laboratory data
showed abnormally elevated levels of total bilirubin
(3.6 mg/dL; normal, 0.2-1.0 mg/dL), AST, ALT, and
γ-GTP. The serum level of CEA was normal; how-
ever, the CA19-9 was above the normal range (47 U/
ml; normal, 0–37 U/ml). An abdominal computed
tomography (CT) scan revealed a 3 cm enhancing
mass located in the hilar bile duct extending to the
left hepatic duct (Fig. 1a) and an enlarged regional
lymph node along the common bile duct (Fig. 1b). In
recent years, for the preoperative biliary drainage in
patients with malignant biliary tract obstruction, we
prefer endoscopic retrograde drainage rather than
percutaneous transhepatic drainage in regard to
adverse events, such as vascular injury and cancer
dissemination. Therefore, an endoscopic retrograde
cholangiopancreatography (ERCP) was performed,
and cholangiography revealed the obstruction of the
hilar to upper portion of bile duct (Fig. 2). And
endoscopic retrograde biliary drainage (ERBD) tube
was placed. A bile duct brush cytologic specimen ob-
tained at the time of ERCP showed small clusters of
relatively small atypical cells with hyperchromatic
nuclei and scant cytoplasm. A salt-and-pepper chro-
matin pattern and cell molding, which are typical in
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neuroendocrine tumors, were not apparent. The cyto-
logic diagnosis at this point was adenocarcinoma,
possibly poorly differentiated. The patient was diag-
nosed with hilar cholangiocarcinoma with regional
lymph node involvement. Abdominal and chest CT
scans showed no other neoplastic lesions. A radical
resection was performed, including an extended left
hepatic lobectomy, excision of the caudate lobe and
the extrahepatic bile duct, dissection of the regional
lymph nodes, and a choledochojejunostomy.
In the resected specimen, the mucosa of the perihi-
lar bile duct was diffusely rough, and the duct wall
was thickened in a 3 cm portion of the proximal
common hepatic duct. Microscopically, the thickened
bile duct wall was infiltrated by irregular islands and
nests of cells with hyperchromatic nuclei and a high
nuclear-to- cytoplasmic ratio (Fig. 3a). The tumor
cells were relatively small, approximately 2 to 3 times
larger than the background lymphocytes (Fig. 3b).
Rosette-like structures were not seen. Numerous mi-
totic figures and apoptotic bodies were present. Im-
munohistochemical stains showed the tumor cells to
be positive for synaptophysin (Fig. 3c) and CD56
(Fig. 3d), and focally positive for chromogranin A.
The Ki-67/MIB-1 Labeling Index was 70 % (Fig. 3e).
Based on these findings, a pathological diagnosis of
small cell neuroendocrine carcinoma was established.
Two out of 8 regional lymph nodes were positive for
metastatic carcinoma.
There were no postoperative complications, and the
patient received 4 courses of adjuvant chemotherapy
with a regimen of irinotecan (50 mg/m2) and carboplatin
(5 AUC/body). Ten months after surgery, there was no
recurrence of the disease.
Discussion
NECs were previously classified as small cell carcinomas
(SCCs), large cell neuroendocrine carcinomas, or poorly
differentiated neuroendocrine carcinomas [3]. NEC is a
poorly differentiated, high-grade, malignant neoplasm
composed of small cells or intermediate to large cells. In
the digestive system, NECs have been reported in the
esophagus, the ampulla of Vater [4], the pancreas [5],
and the gallbladder [6]. However, NECs in the bile duct
are extremely rare.
We conducted a PubMed systematic literature
search (1985–2014) using keywords such as “neuro-
endocrine carcinoma,” “small cell,” and “biliary tract,”
and found only 23 reported cases of NEC of the ex-
trahepatic biliary tracts, excluding the intrahepatic
bile duct, the gallbladder, and the ampulla of Vater
(Table 1, [7–29]). SCC was the most common histo-
logic subtype of NEC of the extrahepatic bile ducts
(19 of 23 cases; Table 1). There were only 3 cases of
A B
Fig. 1 CT findings. Abdominal enhanced computed tomography showed an enhanced tumor located in the hilar bile duct to the left hepatic
duct (a: arrow). The encircled area indicated the regional lymph node metastasis located along the common bile duct (b)
Fig. 2 Cholangiography. Cholangiography revealed the obstruction
of the hilar to upper portion of bile duct (arrow)
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large cell carcinomas of the common bile duct (cases
21 to 23, Table 1). NEC can occur anywhere in the
extrahepatic bile duct, but the middle portion of the
common bile duct appears to be the most common
site of involvement. The prognosis for NEC of the
bile duct appears to be poor. Of the 23 cases with
follow-up data, 57 % (12/23) of the patients died 3
to 20 months after surgery, and only 2 patients were
reported to have survived more than 2 years. NEC of
the biliary system has a high incidence of distant me-
tastasis [15, 16, 19, 20, 22, 24–29]. Consequently, it
has a poor prognosis, and surgical resection alone is
not an effective treatment. A report by Levenson re-
vealed that there is no survival benefit from using
surgery to treat either small cell lung cancer or
extrapulmonary SCC [30]. This may be because the
most important prognostic factor is the extent of dis-
ease at diagnosis, and most patients with extrapul-
monary SCC already have occult metastasis [30]. Of
the 12 patients died within 20 months after surgery,
9 cases were identified their recurrence pattern and
all of them were distant metastases [15, 16, 19, 20,
22, 24, 26, 28, 29]. Meanwhile, the long survival 2
cases had locoregional lymph node metastases without
distant metastasis [13, 27]. Since NEC of the biliary system
had a high incidence of distant metastasis, locolegional
lymph node metastasis could not be a prognostic
factor. In the report of 37 cases of neuroendocrine
tumor of ampulla of Vater, the authors did not find
any prognostic value of the locoregional lymph node
metastases and lymphadenectomy [31].
If there is a biopsy-proven preoperative diagnosis of
NEC, then preoperative chemotherapy can improve the
prognosis in comparison to surgery alone or surgery
with adjuvant chemotherapy. Hazama et al. revealed that
neoadjuvant chemotherapy followed by surgery resulted
in an excellent response for SCC of the common bile
duct [15]. Okamura et al. reported that multidisciplinary
management, consisting of preoperative chemotherapy, a
curative resection, adjuvant chemotherapy, and radiation
therapy, may scontribute to a prolonged survival for
SCC of the common bile duct [26]. In most cases of
NEC of the biliary system diagnosed from pathological
findings of resected specimens, surgical resection
followed by adjuvant chemotherapy is the generally ac-
cepted optimal treatment.
Although there is no established standard treatment
for extrapulmonary SCC, chemotherapy should be
attempted, if possible, because SCC is often chemosensi-
tive [32]. The recommended chemotherapy regimen for
extrapulmonary SCC is the same as that for small cell
lung cancer. For patients with a diagnosis of the small
cell type of NEC who are able to undergo surgical resec-




Fig. 3 Pathological findings. Hematoxylin-eosin stained histologic sections of the resected perihilar bile duct. The tumor cells were arranged in the
cellular nests and cords infiltrating the bile duct wall. The mucosa epithelium was mostly eroded (upper right) (a: ×100). The tumor cells were round
or oval with scant cytoplasm. Numerous mitotic figures and apoptotic bodies are noted (b: ×400). In the immunohistochemical studies, the tumor
cells were diffusely positive for synaptophysin (c: ×400), and CD56 (d: ×400). Approximately 70 % of the tumor cells were positive for Ki-67 (e: ×400)
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etoposide is also recommended for prevention of sys-
temic recurrence [33, 34].
Conclusion
In summary, neuroendocrine carcinoma of the extrahe-
patic biliary tracts is a very rare and highly malignantdi-
sease with a poor prognosis. Although treatment strategies
have not yet been established, a multidisciplinary approach
at diagnosis of NEC of the biliary system, as well as further
studies on therapeutic management could improve the
prognosis of this highly malignant neoplasm.
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Table 1 Neuroendocrine carcinoma of the extrahepatic bile duct. Review of the literature
No. Author Age Sex Histology Location Size Treatment Prognosis
1 Sabanathan (1988) 67 M Small cell Bm 5 cm Palliative bypass and chemo. 6 months, alive
2 Van der Wal (1990) 55 M Small cell + Adenoca. Bm 4 cm Resection N.A.
3 Nishihara (1993) 64 M Small cell + Adenoca. Bh-Bs 1.9 cm Resection 8 months, alive
4 Yamamoto (1998) 71 F Small cell + Adenoca. Bh 6 cm Resection 8 months, dead
5 Kim (2000) 64 M Small cell + Adenoca. Bm 3 cm Resection 1 month, alive
6 Miyashita (2001) 85 F Small cell Bi 3 cm Palliative bypass 5 months, dead
7 Edakuni (2001) 82 F Small cell + Adenoca. Bm 6 cm Resection 45 months, alive
8 Kuraoka (2003) 75 M Small cell Bi 4.5 cm Resection 5 months, alive
9 Hazama (2003) 60 M Small cell CBD 0.3 cm NAC and resection 12 months, dead
10 Arakura (2003) 70 F Small cell Bm 3 cm Resection and chemo. 14 months, dead
11 Park (2004) 60 F Small cell Bs-Bm 3 cm Resection 5 months, dead
12 Thomas (2005) 54 M Small cell Bh-CBD N.A. Resection 6 months, alive
13 Kaiho (2005) 66 F Small cell + Adenoca. Bm 3.5 cm Resection and chemo. 8 months, dead
14 Sato (2006) 68 M Large cell + Adenoca. Bi 2 cm Resection and chemo. 3 months, dead
15 Viana Miguel (2006) 76 M Small cell Bm N.A. Resection, chemo. and irraiation 5 months, alive
16 Jeon (2006) 65 M Small cell Bs-Bm 2 cm Resection and chemo. 12 months, dead
17 Nakai (2008) 32 M Small cell CBD N.A. N.A. N.A.(autopsy)
18 Arakura (2008) 75 M Small cell Bh-Bs 6.5 cm Chemo. and irradiation 10 months, dead
19 Hosonuma (2008) 69 F Small cell Bs-Bm 3 cm Biliary drainage 2 months, alive
20 Okamura (2009) 62 M Small cell Bm 3 cm NAC, resection and irradiation 20 months, dead
21 Yamaguchi (2009) 77 F NEC Bi N.A. Resection and chemo. 27 months, alive
22 Demoreuil (2009) 73 M Large cell + Adenoca. Bh-Bs 3 cm Resection and chemo. 12 months, dead
23 Sasatomi (2013) 76 M Large cell Bh-Bs 5 cm Resection 21 days, dead
24 Current report (2014) 70 F Small cell Bh 5 cm Resection and chemo. 10 months, alive
NEC neuroendocrine carcinoma, NAC neo adjuvant chemotherapy, Adenoca. adenocarcinoma, CBD common bile duct, Bh hilar bile duct, Bs superior portion of
common bile duct, Bm mid portion of bile duct, Bi inferior portion of bile duct, chemo. chemotherapy, N.A. not available, M male, F female
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